High-throughput screening (HTS) of libraries with large numbers of small molecules is a widely recognized and increasingly used method for identifying compounds that modulate biological processes. Compounds thus identified can be powerful molecular probes for dissecting complex biological pathways, and may also be potential leads for clinical use. In the context of biodefense and emerging infectious disease, small molecule HTS could lead to the discovery of new classes of antimicrobial agents or novel stimulators of innate or adaptive immunity, and also identify and validate novel targets for subsequent drug discovery efforts. The National Small Molecule Screening Laboratory for the RCEs in Biodefense and Emerging Infectious Disease (NSRB) was established in 2003 to provide access to small molecule high-throughput screening (HTS) and medicinal chemistry resources for all U.S. investigators conducting research on NIAID Priority Pathogens. It has been a highly successful program and several NSRB projects have produced reagents that are progressing toward possible therapeutic development. The NERCE National Small Molecule Screening and Medicinal Chemistry Core (Core C) propsed here is a continuation of the NSRB. The main goals for Core C are to: Provide access to small-molecule HTS for all U.S. investigators with projects focused on NIAID Priority Pathogens and agents of Emerging Infectious Diseases, and to Provide data analysis and medicinal chemistry resources for maturation of screening positives into smallmolecule research tools or into potential novel therapeutic leads.

Public Health Relevance

Small molecule screening is an important method for identifying agents that affect biological processes and can be applied to the study of infectious disease. Agents discovered by small molecule screening might eventually be developed as therapeutics to treat or prevent microbial infections.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Harvard University
United States
Zip Code
Clark, Margaret J; Miduturu, Chandra; Schmidt, Aaron G et al. (2016) GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem Biol 23:443-52
Russo, Brian C; Stamm, Luisa M; Raaben, Matthijs et al. (2016) Intermediate filaments enable pathogen docking to trigger type 3 effector translocation. Nat Microbiol 1:16025
Kirienko, Daniel R; Revtovich, Alexey V; Kirienko, Natalia V (2016) A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa Virulence. mSphere 1:
Taylor, Travis J; Diaz, Fernando; Colgrove, Robert C et al. (2016) Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology 496:186-93
Chou, Yi-ying; Cuevas, Christian; Carocci, Margot et al. (2016) Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol 90:4494-510
Mellata, Melha; Mitchell, Natalie M; Schödel, Florian et al. (2016) Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis. Vaccine 34:656-62
Helenius, Iiro Taneli; Nair, Aisha; Bittar, Humberto E Trejo et al. (2016) Focused Screening Identifies Evoxine as a Small Molecule That Counteracts CO2-Induced Immune Suppression. J Biomol Screen 21:363-71
Stone, Laura K; Baym, Michael; Lieberman, Tami D et al. (2016) Compounds that select against the tetracycline-resistance efflux pump. Nat Chem Biol 12:902-904
Balasubramanian, Anuradha; Manzano, Mark; Teramoto, Tadahisa et al. (2016) High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antiviral Res 134:6-16
Vrentas, Catherine E; Moayeri, Mahtab; Keefer, Andrea B et al. (2016) A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. J Biol Chem 291:21596-21606

Showing the most recent 10 out of 401 publications